In Q4, 2021 Galapagos biopharma received approval for Jyseleca® for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Jyseleca® was initially approved for moderate to severe active rheumatoid arthritis in 2020. As part of the continued process for rolling-out the key Jyseleca marketing activities in the UC indication. The Jyseleca marketing team organized a meeting to bring together all the key internal stakeholders within the Nordic region.
A cross functional tactical planning meeting was organized to bring together sales, marketing and medical to discuss, and identify key tactical activities as part of their continued efforts to increase the awareness and adoption of Jyseleca within the UC indication, amongst target customers in the Nordics. The meeting was developed using the theme ‘3R’s: Reflect, Recharge, Rollout.
W was asked to support in the communication of the 3R theme to attending delegates, as well as develop tools to help the delegates identify key Jyseleca sales, marketing and medical activities that could be deployed across the Nordics during 2022.
So, based a short deadline, W proposed, developed, and sourced several ideas to be used at the meeting. The deliverables included, developing a 3R logo, 3R brand items (tote bag, coffee mug and writing pad), and designing breakout worksheets and activity cards.
